These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 25731436)

  • 1. [Improvement of the viscosity and the intrahepatic distribution of miriplatin-lipiodol suspension].
    Kishimoto S; Adachi S; Masui A; Suzuki R; Fukushima S
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2101-3. PubMed ID: 25731436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Basic studies on the lipiodolization of miriplatin in combination with CDDP].
    Kishimoto S; Adachi S; Masui A; Suzuki R; Beppu T; Fukushima S
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2104-6. PubMed ID: 25731437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience.
    Kora S; Urakawa H; Mitsufuji T; Osame A; Higashihara H; Yoshimitsu K
    Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1023-9. PubMed ID: 23238851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
    Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
    Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warming effect on miriplatin-lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study.
    Kora S; Urakawa H; Mitsufuji T; Osame A; Higashihara H; Ohki T; Yoshimitsu K
    Hepatol Res; 2013 Oct; 43(10):1100-4. PubMed ID: 23347354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model.
    Tomozawa Y; Nitta N; Ohta S; Otani H; Watanabe S; Sonoda A; Tsuchiya K; Nitta-Seko A; Takahashi M; Murata K
    Jpn J Radiol; 2013 Oct; 31(10):662-7. PubMed ID: 23828788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin).
    Watanabe S; Nitta N; Ohta S; Sonoda A; Otani H; Tomozawa Y; Nitta-Seko A; Tsuchiya K; Tanka T; Takahashi M; Murata K
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):399-405. PubMed ID: 21584842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
    Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
    Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Release Property of Lipiodol Emulsion Formed by Glass Membrane Emulsification Device for Transarterial Chemoembolization.
    Tanaka T; Nishiofuku H; Masada T; Fukuoka Y; Sato T; Tatsumoto S; Matsumoto T; Marugami N; Fujihara M; Kichikawa K
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):135-139. PubMed ID: 31435758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical anticancer effects and toxicologic assessment of hepatic artery infusion of fine-powder cisplatin with lipiodol in vivo.
    Yamaguchi T; Nakajima N; Nakamura I; Mashiba H; Kawashiro T; Ebara K; Ichimura E; Nishimura C; Okamoto K; Ichikawa Y; Ichida T
    Drug Discov Ther; 2013 Oct; 7(5):201-8. PubMed ID: 24270385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
    Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiographic Evaluation of Vascular Damage in Rat Liver After Administration of Epirubicin or Miriplatin.
    Kishimoto S; Aoki H; Suzuki R; Inoue M; Fukushima S
    Anticancer Res; 2018 Jan; 38(1):247-251. PubMed ID: 29277779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of transarterial infusion chemotherapy using cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma.
    Beppu T; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Ogura S; Kasai C; Kusagawa S; Nojiri K; Yoneda M; Fuke H; Yamamoto N; Takei Y; Fujimori M; Hasegawa T; Yamanaka T; Uraki J; Kashima M; Takaki H; Nakatsuka A; Yamakado K; Takeda K
    Anticancer Res; 2012 Nov; 32(11):4923-30. PubMed ID: 23155261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of hepatocarcinoma uptake with radiolabeled lipiodol: development of new lipiodol formulations with increased viscosity.
    Becker S; Lepareur N; Cadeillan V; Ardisson V; Bayat S; Noiret N; Garin E
    Cancer Biother Radiopharm; 2012 Mar; 27(2):149-55. PubMed ID: 22149684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats.
    Hanada M; Baba A; Tsutsumishita Y; Noguchi T; Yamaoka T
    Cancer Sci; 2009 Jan; 100(1):189-94. PubMed ID: 19037997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental assessment of temperature influence on miriplatin and cisplatin iodized-oil suspension viscosity.
    Hasegawa T; Takaki H; Yamanaka T; Fujimori M; Nakatsuka A; Uraki J; Yamada T; Sakuma H; Yamakado K
    Jpn J Radiol; 2013 Jun; 31(6):424-7. PubMed ID: 23525952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models.
    Kan Z; Wright K; Wallace S
    Acad Radiol; 1997 Apr; 4(4):275-82. PubMed ID: 9110025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of stabilized iodized oil emulsion on experimentally induced hepatocellular carcinoma in rats.
    Garin E; Denizot B; Roux J; Noiret N; Lepareur N; Moreau M; Mesba A; Laurent JF; Herry JY; Bourguet P; Benoit JP; Lejeune JJ
    J Vasc Interv Radiol; 2005 Jun; 16(6):841-8. PubMed ID: 15947048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiofrequency ablation after arterial injection of miriplatin-iodized oil suspension into swine liver: ablative zone size and tissue platinum concentration.
    Yamanaka T; Takaki H; Nakatsuka A; Uchida K; Junji U; Fujimori M; Hasegawa T; Yoneda M; Shiraishi T; Sakuma H; Yamakado K
    Cardiovasc Intervent Radiol; 2014 Aug; 37(4):1047-52. PubMed ID: 24232037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature.
    Takaki Y; Kaminou T; Shabana M; Ihaya T; Otsubo K; Ogawa T
    Hepatogastroenterology; 2008; 55(81):202-6. PubMed ID: 18507107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.